Spatial and single-cell transcriptomics decipher butyrate metabolic reprogramming and its impact on colorectal cancer progression and tumor microenvironment remodeling
This study utilizes spatial and single-cell transcriptomics to identify a low-butrate-metabolizing malignant epithelial subgroup in colorectal cancer associated with poor prognosis and stromal crosstalk, revealing that butyrate suppresses tumor progression by inhibiting the HOXB8/AKT/mTOR axis.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Inside the human body, the colon is a busy ecosystem where trillions of bacteria live and work. These microbes break down the fiber we eat from plants, turning it into small chemical molecules called short-chain fatty acids. One of the most important of these is butyrate. In a healthy colon, the cells lining the gut wall act like efficient engines, burning butyrate as their primary fuel to stay strong and keep the intestinal barrier intact. This process helps calm inflammation and keeps the tissue healthy. However, when these cells turn cancerous, their behavior changes drastically. Instead of using butyrate for energy, cancer cells often switch to a different, less efficient way of making energy that ignores this beneficial fuel. This shift is part of a larger mystery: why do some colorectal cancers grow aggressively while others remain slow, and how does the loss of this specific metabolic ability contribute to the disease?
A team of researchers at Peking Union Medical College Hospital and Xuan Wu Hospital set out to solve this puzzle by looking at colorectal cancer through a new lens. They combined two powerful technologies: single-cell transcriptomics, which reads the genetic instructions of individual cells to see what they are doing, and spatial transcriptomics, which maps exactly where those cells are located within the tissue. By analyzing data from dozens of patients, they discovered that the cancer cells which had lost the ability to process butyrate were the most dangerous. These cells were not just passive victims of the disease; they were the drivers of its worst features. The study reveals that when cancer cells stop using butyrate, they become more like immature stem cells, growing faster, spreading more easily, and forming a protective shield around themselves that blocks the immune system.
The researchers found that this dangerous state is controlled by a specific genetic switch called HOXB8. In healthy cells, butyrate helps keep this switch turned off. But in the aggressive cancer cells that cannot process butyrate, the HOXB8 switch is stuck in the "on" position. This high level of HOXB8 activity acts like a master regulator, turning on a cascade of signals that tell the cell to divide rapidly and invade surrounding tissues. To prove this connection, the scientists treated human colorectal cancer cells in a lab dish with sodium butyrate, a form of the beneficial molecule. They observed that the treatment successfully lowered the levels of HOXB8. As a result, the cancer cells stopped growing as fast, lost their ability to migrate, and became more likely to die off naturally. When the researchers forced the cells to keep HOXB8 turned on even while treating them with butyrate, the drug's protective effects were significantly diminished. This confirmed that the ability of butyrate to fight cancer is primarily mediated through its capacity to silence this specific genetic switch.
Beyond the cancer cells themselves, the study uncovered how these cells interact with their neighbors. Using spatial mapping, the researchers saw that the aggressive, low-butyrate cancer cells tend to cluster closely with fibroblasts, which are structural cells that normally support tissue. These cancer cells send signals to the fibroblasts, and the fibroblasts respond by remodeling the environment to help the tumor grow and hide from the immune system. This creates a supportive neighborhood for the cancer, making it harder for the body's defenses to attack. The researchers also built a computer model based on the genes involved in this process. This model can look at a patient's tumor data and predict how aggressive the cancer is likely to be, separating patients into high-risk and low-risk groups with high accuracy. The high-risk group, characterized by low butyrate metabolism, showed signs of an immune system that was present but unable to function, a state that explains why these patients often respond poorly to standard immunotherapies.
The findings suggest a clear path forward for understanding and treating colorectal cancer. The loss of butyrate metabolism is not just a side effect of the disease but a central driver that reprograms the cancer cell into a more dangerous form. By targeting the HOXB8 switch and the signaling pathways it controls, specifically the AKT/mTOR pathway which regulates cell growth, it may be possible to reverse this aggressive behavior. The study points to the potential of using metabolic interventions, such as butyrate-based therapies, to retrain these cancer cells. While the research is still in the early stages and requires further testing in diverse patient populations, it offers a concrete explanation for why some tumors are so resilient and provides a new set of targets for developing treatments that could improve outcomes for patients with this challenging disease.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.